AEV 103
Alternative Names: 3,6’-dithiopomalidomide; 3,6’-DP; AEV-103Latest Information Update: 13 Apr 2022
At a glance
- Originator National Institutes of Health (USA)
- Developer AevisBio; National Institute on Aging; National Institutes of Health (USA); Yonsei University
- Class Imides; Small molecules
- Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease; Brain injuries
Most Recent Events
- 12 Apr 2022 AEV 103 is under IND-enabling studies in South Korea (AevisBio pipeline, April 2022)
- 08 Mar 2022 Preclinical trials in Brain injuries in South Korea (unspecified route) (AevisBio pipeline, March 2022)
- 08 Mar 2022 Pharmacodynamics data from a preclinical study in Alzheimer's disease released in AevisBio